Agenus Inc. (NASDAQ:AGEN) Given Consensus Recommendation of “Hold” by Analysts

Shares of Agenus Inc. (NASDAQ:AGEN) have earned an average recommendation of “Hold” from the five research firms that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating on the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $14.50.

A number of research firms recently commented on AGEN. Weiss Ratings reissued a “sell (e+)” rating on shares of Agenus in a report on Monday, December 29th. Wall Street Zen raised shares of Agenus from a “hold” rating to a “buy” rating in a report on Saturday, March 21st.

Agenus Stock Performance

Agenus stock traded down $0.01 during midday trading on Friday, reaching $3.43. The company’s stock had a trading volume of 79,379 shares, compared to its average volume of 619,215. The firm has a market capitalization of $131.71 million, a PE ratio of -7.41 and a beta of 1.57. Agenus has a fifty-two week low of $1.38 and a fifty-two week high of $7.34. The stock’s 50 day simple moving average is $3.20 and its 200 day simple moving average is $3.75.

Agenus (NASDAQ:AGEN) last posted its quarterly earnings results on Monday, March 16th. The biotechnology company reported $0.56 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.27) by $1.83. The business had revenue of $34.20 million for the quarter, compared to analysts’ expectations of $28.10 million. Agenus had a negative net margin of 2.67% and a negative return on equity of 7.65%. Equities analysts predict that Agenus will post -12.55 earnings per share for the current year.

Institutional Trading of Agenus

Institutional investors have recently bought and sold shares of the company. EP Wealth Advisors LLC purchased a new stake in Agenus during the fourth quarter worth $31,000. Jump Financial LLC purchased a new position in shares of Agenus in the second quarter valued at $55,000. Traynor Capital Management Inc. acquired a new position in shares of Agenus during the 3rd quarter worth $50,000. R Squared Ltd acquired a new position in shares of Agenus during the 4th quarter worth $41,000. Finally, Squarepoint Ops LLC purchased a new stake in shares of Agenus in the 3rd quarter worth about $54,000. 61.46% of the stock is currently owned by hedge funds and other institutional investors.

About Agenus

Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.